COLL Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of 13.07%. Collegium Pharmaceutical's return on equity of 19.31% beat Corcept Therapeutics's return on equity of 21.3%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 26.85%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 92.33%. Given that Corcept Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Corcept Therapeutics is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.639, which suggesting that the stock is 36.077% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.154, suggesting its less volatile than the S&P 500 by 84.623%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Corcept Therapeutics quarterly revenues of $157.2M. Collegium Pharmaceutical's net income of $2.4M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 26.66x while Corcept Therapeutics's PE ratio is 61.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.88x versus 12.16x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of -208.09%. Collegium Pharmaceutical's return on equity of 19.31% beat Nutriband's return on equity of -102.63%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 26.85%. On the other hand Nutriband has an analysts' consensus of $15.00 which suggests that it could grow by 88.44%. Given that Nutriband has higher upside potential than Collegium Pharmaceutical, analysts believe Nutriband is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.639, which suggesting that the stock is 36.077% less volatile than S&P 500. In comparison Nutriband has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.565%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Nutriband quarterly revenues of $667.4K. Collegium Pharmaceutical's net income of $2.4M is higher than Nutriband's net income of -$1.4M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 26.66x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.88x versus 36.83x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of 21.63%. Collegium Pharmaceutical's return on equity of 19.31% beat Pfizer's return on equity of 8.72%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 26.85%. On the other hand Pfizer has an analysts' consensus of $29.14 which suggests that it could grow by 13.62%. Given that Collegium Pharmaceutical has higher upside potential than Pfizer, analysts believe Collegium Pharmaceutical is more attractive than Pfizer.

Collegium Pharmaceutical has a beta of 0.639, which suggesting that the stock is 36.077% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.63% to investors and pays a quarterly dividend of $0.43 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Collegium Pharmaceutical's net income of $2.4M is lower than Pfizer's net income of $3B. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 26.66x while Pfizer's PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.88x versus 2.34x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of -7.89%. Collegium Pharmaceutical's return on equity of 19.31% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 26.85%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 17.75%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.639, which suggesting that the stock is 36.077% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.700, suggesting its less volatile than the S&P 500 by 30.01%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Collegium Pharmaceutical's net income of $2.4M is higher than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 26.66x while Supernus Pharmaceuticals's PE ratio is 29.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.88x versus 2.78x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.